Amplia Therapeutics Ltd. (INNMF)
OTHER OTC:INNMF
INNMF Stock Chart & Stats
$0.09
$0.02(38.01%)
At close: 4:00 PM EST
$0.09
$0.02(38.01%)
Day’s Range― - ―
52-Week Range$0.03 - $0.27
Previous CloseN/A
Volume1.10K
Average Volume (3M)12.53K
Market Cap
$81.30M
Enterprise Value$102.06M
Total Cash (Recent Filing)$29.16M
Total Debt (Recent Filing)$381.42K
Price to Earnings (P/E)―
Beta-0.77
Next Earnings
Jun 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding513,071,660
10 Day Avg. Volume2,756
30 Day Avg. Volume12,526
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)1.02
Price to Sales (P/S)5.68
P/FCF Ratio-3.12
Enterprise Value/Market Cap1.26
Enterprise Value/Revenue42.94
Enterprise Value/Gross Profit46.37
Enterprise Value/Ebitda-9.50
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsAmplia’s reported gross margins near 90–100% indicate favorable underlying unit economics for its therapeutics. High product-level margins provide structural leverage as revenue scales, supporting durable pricing power and the prospect of faster operating profitability once fixed R&D and SG&A costs moderate.
Improving Revenue TrajectoryRevenue rising to ~$3.8m in FY2025 from a tiny base shows the company is generating growing top-line traction. A sustained upward revenue trend reduces binary clinical-stage risk, improves visibility for near-term planning, and establishes the foundation for future operating leverage as programs progress.
Conservative Capital StructureMinimal debt and low leverage materially lower financial distress risk and interest burden. This conservative balance sheet provides runway flexibility, makes fundraising less immediately urgent, and preserves optionality while clinical development advances, benefiting strategic decision-making over months.
Bears Say
Persistent Negative Cash FlowOperating and free cash flow are negative each year and cash burn rose in FY2025. Persistent and increasing cash outflows create recurring funding requirements, raising the probability of dilutive capital raises or dependency on partner milestone payments and constraining strategic flexibility.
Deep, Ongoing Net LossesAmplia is still deeply loss-making with net losses far exceeding revenue. Prolonged negative profitability erodes shareholder equity, delays the path to self-sufficiency, and increases reliance on external financing or partnerships to sustain clinical and commercialization activities over the medium term.
Negative Returns On Equity And Equity VolatilityPersistent negative ROE and a notable equity dip in FY2024 signal shareholder value erosion and an inconsistent capital base. This volatility can undermine investor confidence, complicate future fundraising terms, and reflect dilution or write-down risks that impair long-term capital planning.
Amplia Therapeutics News
INNMF FAQ
What was Amplia Therapeutics Ltd.’s price range in the past 12 months?
Amplia Therapeutics Ltd. lowest stock price was $0.03 and its highest was $0.27 in the past 12 months.
What is Amplia Therapeutics Ltd.’s market cap?
Amplia Therapeutics Ltd.’s market cap is $81.30M.
When is Amplia Therapeutics Ltd.’s upcoming earnings report date?
Amplia Therapeutics Ltd.’s upcoming earnings report date is Jun 01, 2026 which is in 66 days.
How were Amplia Therapeutics Ltd.’s earnings last quarter?
Amplia Therapeutics Ltd. released its earnings results on Nov 27, 2025. The company reported -$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.007.
Is Amplia Therapeutics Ltd. overvalued?
According to Wall Street analysts Amplia Therapeutics Ltd.’s price is currently Overvalued.
Does Amplia Therapeutics Ltd. pay dividends?
Amplia Therapeutics Ltd. does not currently pay dividends.
What is Amplia Therapeutics Ltd.’s EPS estimate?
Amplia Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amplia Therapeutics Ltd. have?
Amplia Therapeutics Ltd. has 513,071,660 shares outstanding.
What happened to Amplia Therapeutics Ltd.’s price movement after its last earnings report?
Amplia Therapeutics Ltd. reported an EPS of -$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Amplia Therapeutics Ltd.?
Currently, no hedge funds are holding shares in INNMF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amplia Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
INNMF Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $153.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
66.66%
12-Months-Change
Fundamentals
Return on Equity
-24.81%
Trailing 12-Months
Asset Growth
199.58%
Trailing 12-Months
Company Description
Amplia Therapeutics Ltd.
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Technical Analysis
Tryptamine Therapeutics
―
Neuren Pharmaceuticals Limited
―
Paradigm Biopharmaceuticals
―
Alterity Therapeutics
―
Zelira Therapeutics
―
Ownership Overview
Options Prices
Currently, No data available
---